The Basics

Benefits of biosimilars

One of the fundamental benefits of biosimilars is that, while they offer therapeutically equivalent outcomes to originator biotherapeutic medicines, they do so at a reduced cost.

Reduced costs

On a clinician level, this may enable clinicians to initiate treatment earlier (because it is now more affordable), whereas on a collective (or medical scheme) level, it means that more patients can be treated within the same budget.1 Due to the reduced costs, doctors are now in a position to prescribe high-quality, safe and efficacious medicines allowing more of their patients access to state-of-the-art treatment at earlier stages of diseases that are, in their course, disabling and/or life-threatening.

Value-added services for patient support

In addition, the availability of biosimilars drives competition and this in turn produces increased treatment options and value-added services to support patient care.5

A further benefit of biosimilar products is that their development may use the latest state-of-the-art analytical and biotechnology methods, which may include some that might not have been available when the originator (or reference) product was first approved.1

Potential of biosimilars for patients, payers and providers

Additional treatment choices at potentially lower cost
May increase access to biologics, which may lead to better health outcomes overall
Possible savings and efficiencies
Offer a variety of therapeutic options